Bluett-Duncan, M, Astill, D, Charbak, R, Clayton-Smith, J, Cole, S, Cook, P A, Cozens, J, Keely, K, Morris, J, Mukherjee, R, Murphy, E, Turnpenny, P, Williams, J, Wood, A G, Yates, L M and Bromley, R L (2023). Neurodevelopmental outcomes in children and adults with Fetal Valproate Spectrum Disorder: A contribution from the ConcePTION project. Neurotoxicology and teratology, 100 ,
Abstract
Aim: To describe the neurodevelopmental phenotype of older children and adults with a diagnosis of Fetal Valproate Spectrum Disorder (FVSD). Methods: In this cross-sectional study, 90 caregivers were recruited and completed a series of questionnaires regarding the neurodevelopmental outcomes of 146 individuals aged 7–37 years (M = 18.1), including individuals with a formal diagnosis of FVSD (n = 99), individuals exposed to Valproate but without an FVSD diagnosis (n = 24), and individuals not exposed to Valproate (N = 23). The mean dose of valproate exposure for individuals with an FVSD diagnosis was 1470 mg/day. Results: Individuals with a diagnosis of FVSD showed significantly higher levels of moderate (43.4%) and severe (14.4%) cognitive impairment than other groups (p = 0.003), high levels of required formal educational support (77.6%), and poorer academic competence than individuals not exposed to Valproate (p = 0.001). Overall psychosocial problems (p = 0.02), internalising problems (p = 0.05) and attention problems (p = 0.001), but not externalising problems, were elevated in individuals with a diagnosis of FVSD. Rates of neurodevelopmental disorders, particularly autistic spectrum disorders (62.9%) and sensory problems (80.6%) are particularly central to the FVSD phenotype. There was no evidence of a statistical dose-dependent effect, possibly due to the high mean dose of exposure having a uniformly negative impact across the sample. Individuals with FVSD had required a significant number of health and child development services. Interpretation: Children and young adults with a diagnosis of FVSD are at an increased risk of a range of altered neurodevelopmental outcomes, highlighting the need for a multidisciplinary approach to clinical management across the lifespan.
Publication DOI: | https://doi.org/10.1016/j.ntt.2023.107292 |
---|---|
Divisions: | College of Health & Life Sciences > School of Psychology |
Additional Information: | © 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) |
Uncontrolled Keywords: | Cognition,Epilepsy,Teratology,Neurodevelopment,Fetal Valproate Spectrum Disorder,Sodium Valproate |
Publication ISSN: | 1872-9738 |
Last Modified: | 07 Oct 2024 07:52 |
Date Deposited: | 18 Sep 2023 09:54 |
Full Text Link: | |
Related URLs: |
https://www.sci ... 1423?via%3Dihub
(Publisher URL) http://www.scop ... tnerID=8YFLogxK (Scopus URL) |
PURE Output Type: | Article |
Published Date: | 2023-11-01 |
Published Online Date: | 2023-09-04 |
Accepted Date: | 2023-09-01 |
Submitted Date: | 2023-04-12 |
Authors: |
Bluett-Duncan, M
Astill, D Charbak, R Clayton-Smith, J Cole, S Cook, P A Cozens, J Keely, K Morris, J Mukherjee, R Murphy, E Turnpenny, P Williams, J Wood, A G ( 0000-0002-1537-6858) Yates, L M Bromley, R L |